Search the Newsreel

Cytosorbents Corporation 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:CTSO) 2026-08-09

This document contains the Q2 2026 earnings call transcript for Cytosorbents Corp (NAS:CTSO), held on August 6, 2026. Key points from the call indicate a significant reduction in operating cash burn, improved gross margins, and growth in the distributor network revenue. However, challenges include …

US$2.88: That's What Analysts Think Cytosorbents Corporation (NASDAQ:CTSO) Is Worth After Its Latest Results

CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update

CytoSorbents Corporation reported its Q2 2026 financial results, with revenue unchanged at $9.6 million but an improved gross margin of 73%. The company reduced its operating loss by 27% and adjusted EBITDA loss by 38%, aiming for operating cash flow breakeven in the second …

Cytosorbents Corp (CTSO) Stock News Today

This article provides recent news and financial updates for Cytosorbents Corp (CTSO). The company's stock experienced a 9.68% decline. The latest earnings report indicates that CytoSorbents' Q2 2026 earnings showed improved margins despite flat revenue.

CytoSorbents (NASDAQ: CTSO) posts Q2 2026 revenue of $9.6M and narrows loss

CytoSorbents reported Q2 2026 revenue of $9.6 million, flat year-over-year, driven by growth from distributors and direct international sales offsetting a decline in Germany. The company narrowed its operating loss to ($2.6 million) and achieved a net income of $1.9 million, or $0.03 per …

Earnings call transcript: Cytosorbents posts modest Q2 2026 revenue beat

Cytosorbents reported a modest revenue beat in Q2 2026, with revenue of $9.6 million slightly exceeding Wall Street expectations. The company demonstrated operational improvements, including increased gross margins, reduced operating expenses, and a significant decrease in operating cash burn, aiming for breakeven in H2 …

CytoSorbents (NASDAQ: CTSO) Q2 loss, higher margins and four value drivers

CytoSorbents reported a Q2 2026 net loss of $4.417 million, compared to a net income of $1.947 million a year prior, despite product gross margin improving to 73%. The company highlighted significant improvements in Adjusted EBITDA loss and operating cash burn, attributing them to …

Cytosorbents Corp 2Q 2026: Revenue $9.63M, EPS ($0.07) — 10-Q Summary

Cytosorbents Corp reported its second-quarter 2026 financial results, with revenue holding steady year-over-year at $9.63 million but posting a loss per share of ($0.07), a decline from the prior year's profit. The company is focusing on strategic initiatives such as channel shifts, cost reductions, …

Cytosorbents Crp earnings missed by $0.01, revenue topped estimates

CytoSorbents (Nasdaq: CTSO) flags going concern as cash falls to $5.9M

Cytosorbents Corp (HQE1) Q1 2023 Earnings Report - Results, Call & Slides

Cytosorbents Corp (HQE1) reported its Q1 2023 earnings, missing consensus EPS expectations with an actual EPS of -CHF0.14 against a consensus of -CHF0.10. However, the company surpassed revenue forecasts, achieving CHF7.63M compared to the expected CHF7.06M, marking an 8.72% year-over-year growth. The earnings call …

Cytosorbents Corp (CTSO) Financial Health: Profitability & Balance Sheet Analysis

Cytosorbents Corp (CTSO) has a weak financial status and average operating efficiency, ranking 155 out of 199 in the Healthcare Equipment & Supplies industry with a score of 6.39. Despite its overall weak financial health, the company recently reported a 1.57% year-over-year revenue increase …

Cytosorbents Corp (CTSO) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a detailed risk assessment for Cytosorbents Corp (CTSO), focusing on its volatility, financial, and investment risks. The company's risk assessment score is 2.46, ranking 152 out of 199 in the Healthcare Equipment & Supplies industry, with a beta of 1.37 indicating …

Cytosorbents Corp (CTSO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Cytosorbents Corp (CTSO), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. As of July 29, 2026, CTSO has a price momentum score of 4.35 and is trading between a …

CTSO|Cytosorbents Corp|Price:0.350|Chg%:-0.004

This article provides a comprehensive stock analysis of Cytosorbents Corp (CTSO) by TradingKey, highlighting its financial health, valuation, growth potential, and institutional confidence. Despite weak recent stock market performance, the company shows strong fundamentals and significant growth potential, although its valuation is considered fairly …

Cytosorbents Corp (CTSO) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on the dividend and stock split history for Cytosorbents Corp (CTSO). It indicates that the company has distributed a total of $0.00 in dividends over the past five years and currently shows no specific data for past dividend payments. The …

CytoSorbents Market Sentiment

This article provides an overview of market sentiment for CytoSorbents (CTSO), including analyst consensus, short interest, options flow, and insider activity. It highlights that analysts have a "Buy" consensus with an average price target of $6, while short interest is 3.6% and rising, indicating …

Cytosorbents Corp (CTSO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Cytosorbents Corp (CTSO), focusing on its regional revenue contributions. As of the reported data, the company's revenue is primarily driven by "All Other" regions (67.62%), followed by Germany (31.71%), and the United States (0.67%). Details on business …

Cytosorbents Corp (CTSO) Cash Flow

This article provides an in-depth look at Cytosorbents Corp's (CTSO) cash flow statements, including operating, investing, and financing activities, spanning multiple fiscal quarters and years. It details various financial metrics such as net income, operating gains/losses, changes in working capital, capital expenditures, and free …

Cytosorbents Corp (CTSO) Institutional Confidence

Cytosorbents Corp (CTSO) has an institutional shareholding score of 3.00, placing it 131st out of 200 in the Healthcare Equipment & Supplies industry. Institutional shareholding proportion decreased by 10.95% quarter-over-quarter to 25.84%. James Simons is the largest institutional shareholder, holding 0.16% of outstanding shares.

Cytosorbents Corp (CTSO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Cytosorbents Corp (CTSO), highlighting its current valuation score of 8.71 within the Healthcare Equipment & Supplies industry. It details the company's P/E ratio, noting its current value is -1.90, which is significantly below its recent high and …

Cytosorbents Corp (CTSO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Cytosorbents Corp (CTSO), listing major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent shareholder activities by key investors.

CTSO|Cytosorbents Corp|Price:0.361|Chg%:-0.021

Cytosorbents Corp (CTSO) is trading at $0.360, down 0.39%. Its market capitalization is $22.62M. The company, which specializes in blood purification technologies, is considered fairly valued with significant growth potential, although its stock price is expected to trend down in the medium term. Analysts …

CytoSorbents (CTSO) to Release Q2 Financial Results on July 30

CytoSorbents Corp (CTSO) is scheduled to release its second-quarter financial results on July 30, 2026, after market hours. The company, which specializes in blood purification technologies, is currently considered 56.2% undervalued with a GF Value™ of $0.89 against a current price of $0.39, but …

CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights

CytoSorbents Corporation (NASDAQ: CTSO) will report its second quarter 2026 financial results and business highlights on Thursday, August 6, 2026, after market close. Management will host a conference call and webcast at 4:30 PM ET the same day to discuss the results and provide …

CTSO Q1 2026 Earnings: EPS Misses Estimates Amid Continued Operational Challenges - EBITDA Estimate Trend

Chatham Rock Phosphate Limited Ordinary Shares (NZX: CRP) - Share Price

Chatham Rock Phosphate Limited Ordinary Shares (NZX:CRP)

Chatham Rock Phosphate Stock Price Forecast. Should You Buy CRP.NZ?

Chatham Rock Phosphate Limited (CRP.NZ) valuation measures and financial statistics

Chatham Rock Phosphate Ltd (NZP.V) Stock Price, News, Quote & History

Chatham phosphate mining consent refused